PSMAddition data show Novartis Pluvicto delays progression to end-stage prostate cancer
Basel, October 19, 2025 – Novartis today presents new Pluvictoâ„¢ (lutetium (177Lu)…
Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition…